jak in 14

JAK-IN-14 (compound 16) is a specific JAK1 inhibitor with IC50<5 μM. It prevents JAK1 phosphorylation by binding to the active site of JAK1, and is more than 8-fold selective for JAK1 over JAK2/JAK3, and can be used in immune, inflammation and cancer research.

JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.

JAK1-IN-14 (Compound12a) is a potent and selective inhibitor of JAK1, effectively inhibiting JAK1 and JAK2 with IC50 values of 12.6 nM and 135 nM, respectively. It reduces liver fibrosis levels and is applicable for research related to liver fibrosis and inflammatory diseases.

JAK-IN-20 is a potent, orally active, broad-based JAK inhibitor, effective on JAK1 (IC50: 7 nM), JAK2 (IC50: 5 nM), and JAK3 (IC50: 14 nM), exhibiting excellent pharmacokinetic and anti-inflammatory activity in vivo.